Positive catalysts are aligning for Spectra7 Microsystems, says Mackie


Increasing revenue for Spectra7 Microsystems (TSXV:SEV) has Mackie Research Capital analyst Nikhil Thadani feeling bullish about the company’s near term prospects. Yesterday, Spectra7 announced that it had confirmed orders or bookings of (U.S.) $2.5-million during the third quarter of 2015, an 85% increase over the same period last year. The company said majority of its […]

Carmanah Technologies climbs as Q3 revenue rises 60%


Shares of Carmanah Technologies (TSX:CMH) are up today after the company released preliminary results that saw its topline climb substantially. Ahead of its November 13 third quarter earnings report, Carmanah said its revenue would come in at about (U.S.) $19.5-million, up approximately 60% from the $12.2-million topline the company posted in last year’s Q3. “The […]

Nobilis Health is my top pick for Q4, says Mackie’s Stanley


With worldwide markets down substantially heading into the fourth quarter of 2015, Mackie Research Capital analyst Russell Stanley says he has identified a healthcare play that will buck the trend. In a comprehensive report from Mackie Research Capital dedicated to their analyst’s top picks for Q4, Stanley says Nobilis Health Corp. (NHC-TSX) is his. Nobilis, […]

Apivio CEO Rob Bakshi catches up with Cantech Letter


When we first caught up with Apivio (TSXV:APV) CEO Rob Bakshi, he was looking to overcome the idea that the hardware focused company could transition to higher margin business without affecting its topline. Apivio, which was founded in 2003 in South Korea, imagined that desktop phones would become the kind of feature-packed devices that users […]

Com Dev rises on rumours that it will be sold

com dev

Shares of Com Dev (TSX:CDV) are up sharply today on rumours the company will be sold. After being halted less than an hour into the trading day, the company issued a statement confirming the rumours but did not provide any detail on a particular transaction. “Com Dev acknowledges that, in connection with a review of […]

Cipher Pharmaceuticals gets upgraded to “Buy” at Laurentian


The settling of an outstanding lawsuit removes the overhang from Cipher Pharmaceuticals (TSX:CPH, Nasdaq:CPHR) and will likely signal the end of a long share price decline, says Laurentian Bank Securities analyst Joseph Walewicz. Yesterday, Cipher Pharmaceuticals and its partners Ranbaxy Pharmaceuticals Galephar Pharmaceutical Research announced they had entered into a settlement agreement with Actavis Laboratories […]

Medicure is undervalued, says PI Financial


Specialty pharmaceutical company Medicure (TSX:MPH) has only begun to realize the potential of cardiovascular drug Aggrastat, says PI Financial analyst Sheila Broughton. In a research report to clients yesterday, Broughton initiated coverage of Medicure with a “Buy” recommendation, and one year target price of $5.75. The analyst’s risk rating is “Speculative”. Aggrastat belongs to a […]

Did this Canadian man predict space travel in 1861?

The Reverend William Leitch.

There are futurists and then there are futurists. More than four decades before the Wright Brothers got an airplane off the ground at Kitty Hawk, a Canadian man predicted rocket-based space space flight, says one historian. In a new study published in the The First Scientific Concept of Rockets for Space Travel, space historian Robert […]